Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $328.2 million.

  • Roivant Sciences' Cash from Financing Activities rose 13147.72% to $328.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$839.6 million, marking a year-over-year increase of 3827.82%. This contributed to the annual value of -$1.2 billion for FY2025, which is 39086.76% down from last year.
  • Roivant Sciences' Cash from Financing Activities amounted to $328.2 million in Q4 2025, which was up 13147.72% from $62.6 million recorded in Q3 2025.
  • Over the past 5 years, Roivant Sciences' Cash from Financing Activities peaked at $452.0 million during Q4 2023, and registered a low of -$1.0 billion during Q4 2024.
  • Its 5-year average for Cash from Financing Activities is $6.8 million, with a median of $62.6 million in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 293165.78% in 2023, then plummeted by 893530.83% in 2024.
  • Roivant Sciences' Cash from Financing Activities (Quarter) stood at $305.7 million in 2021, then decreased by 5.43% to $289.1 million in 2022, then surged by 56.33% to $452.0 million in 2023, then crashed by 330.68% to -$1.0 billion in 2024, then soared by 131.48% to $328.2 million in 2025.
  • Its Cash from Financing Activities stands at $328.2 million for Q4 2025, versus $62.6 million for Q3 2025 and -$187.8 million for Q2 2025.